Tag: licensing
-
Organ Chip Spin-Off Gains $28M in Venture Funds
28 March 2016. A two year-old company developing chip devices that simulate human organs is adding $28 million in venture capital to its treasury. This is the second venture funding round for Emulate Inc., in Boston, a spin-off enterprise from the Wyss Institute for Biologically Inspired Engineering at Harvard University. Emulate Inc. creates plastic chip…
-
Regeneron, Bayer Collaborating on Eye Disorder Drug
24 March 2016. Regeneron Pharmaceuticals and drug-maker Bayer AG are developing a combination of biologic drugs to treat the eye disorders wet age-related macular degeneration and diabetic macular edema. The agreement — the third such deal between the companies — is expected to bring Regeneron as much as $130 million if all milestones are met.…
-
New Biotech Begins Work on Enhanced Platinum Cancer Drugs
23 March 2016. A new biotechnology company began work today on developing improved platinum-based treatments for solid tumor cancers. The company, Placon Therapeutics in Cambridge, Massachusetts, is a spin-off enterprise from Tarveda Therapeutics, a developer of biologic cancer drugs. Placon Therapeutics focuses on new treatments for cancer using platinum as a cancer-killing agent that works…
-
Merck Licensing Harvard Cancer Drug Molecules
21 March 2016. The pharmaceutical company Merck is licensing small molecule research discoveries from a Harvard University lab as potential treatments for leukemia. The agreement brings the university $20 million immediately, with further payments expected as Merck develops the discoveries into products. The deal gives Merck an exclusive license to research by biochemistry professor Matthew…
-
Allied-Bristol Licenses NYU Research, Starts New Company
17 March 2016. Allied-Bristol Life Sciences, a joint venture of Allied Minds and Bristol-Myers Squibb, is licensing research from New York University on signaling pathways affecting growth of tumors, for a new company begun under its tutelage. Financial aspects of the deal between Allied-Bristol and NYU were not disclosed. The new enterprise, known as iBeCa…
-
Roche Licensing Biotech Immunotherapies in $1B Deal
15 March 2016. The biotechnology company Blueprint Medicines, a developer of cancer treatments based on a patient’s precise genomic make-up, is partnering with the pharmaceutical company Roche on cancer immunotherapies. The agreement gives Roche options to license up to 5 small-molecule, or low molecular-weight therapies, in a deal that could bring Blueprint more than $1…
-
Multiple Myeloma Gene Therapy Trial Underway
19 February 2016. The biotechnology company bluebird bio began testing its experimental gene therapy for multiple myeloma in an early-stage clinical trial. The Cambridge, Massachusetts company — which spells its name in all lower-case letters — is also licensing the technology tested in the trial to the pharmaceutical company Celgene. Multiple myeloma is a cancer of…
-
Biotech Reviewing Stanford Immuno-Stem Cell Technology
16 February 2016. A biotechnology company in Los Angeles is evaluating a technology developed at Stanford University for transferring DNA of immune system cells to a patient’s own stem cells to produce immunotherapies for treating cancer. The agreement with Stanford gives ImmunoCellular Therapeutics Ltd. an option to license the technology from the lab of immunologist…
-
Start-Up Licensing Wayne State Neurological Discoveries
8 February 2016. Wayne State University is licensing research discoveries from its pharmacy school to a new enterprise for development as drugs to treat depression, post-traumatic stress disorder or PTSD, and other neurological disorders. Financial aspects of the agreement with Trimaran Pharma Inc. were not disclosed. The deal covers research by pharmaceutical sciences professor Aloke…
-
Genome-Editing Company Raises $94 Million in IPO
3 February 2016. Editas Medicine, developer of treatments for disease that harness editing of the human genome, is raising $94.4 million in its initial public stock offering. The company, trading on the Nasdaq exchange under the symbol EDIT, issued 5.9 million shares priced at $16.00. As of 12 noon on 3 February, the stock is…